For the Inventor, By the Inventor

Enter assignee name

Hennigsdorf, Germany

B.r.a.h.m.s Gmbh

Calculating rank

USPTO Granted Patents = 78

% Expired Patents = 19.2

EPO Patents = 73

Trademarks = 10

Forward Citations = 264

Loading Chart...

Loading Chart...

73 inventors (with patents filed for the assignee):

Andreas Bergmann (49 out of 109 patents)

Joachim Struck (48 out of 65 patents)

Nils G Morgenthaler (18 out of 21 patents)

4. Jana Papassotiriou (13 out of 13 patents)

5. Darius Cameron Wilson (9 out of 9 patents)

6. Leong Loke Ng (6 out of 6 patents)

7. Aline Pehla (5 out of 5 patents)

8. Oliver Hartmann (4 out of 5 patents)

9. Stefan Kirsch (4 out of 4 patents)

10. Hans Rupprecht (3 out of 3 patents)

11. Stefan Blankenberg (3 out of 3 patents)

12. Karl Lackner (3 out of 4 patents)

13. Christoph Bickel (3 out of 3 patents)

14. Gilbert Vassart (3 out of 19 patents)

15. Sabine Costagliola (3 out of 3 patents)

Core Competencies:

Procalcitonin

Proadrenomedullin

Biomarkers

Risk Stratification

Infections

Cardiac Diseases

Chronic Conditions

Diagnostic Methods

Immunoassay

Neurodegenerative Diseases

Acute Coronary Syndrome

Heart Failure

78 patents: Sort by Forward Citations

1. 12681017 - PRO-ADRENOMEDULLIN FOR PROGNOSING DISEASE PROGRESSION IN SEVERE ACUTE RESPIRATORY SYNDROME (SARS) (2026-07-14),

2. 12560620 - Pro-ADM for Prognosis of Trauma-Related Complications in Polytrauma Patients (2026-02-24),

3. 12517138 - METHOD FOR GUIDANCE OF FLUID THERAPY BASED ON PROADRENOMEDULLIN (2026-01-06),

4. 12442825 - Prescription of remote patient management based on biomarkers (2025-10-14),

5. 12405279 - Method for preparing a sample (2025-09-02),

6. 12385926 - MMP-8 as a marker for identifying infectious disease (2025-08-12),

7. 12265092 - Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin (2025-04-01),

8. 12181474 - Biomarkers for the diagnosis of invasive fungal infections (2024-12-31),

9. 12153057 - Antibiotic therapy guidance based on procalcitonin in patients with comorbidities (2024-11-26),

10. 12000845 - Method for discharging a patient from an intensive care unit (2024-06-04),

11. 11835531 - Procalcitonin for the prognosis of adverse events (2023-12-05),

12. 11592450 - Diagnosis and risk stratification of fungal infections (2023-02-28),

13. 11402393 - Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints (2022-08-02),

14. 11391742 - Free histone proteins as biomarkers (2022-07-19),

15. 11327082 - Proadrenomedullin as a marker for abnormal platelet levels (2022-05-10),

Company Overview

B.r.a.h.m.s GmbH, based in Hennigsdorf, Germany, specializes in biomarker diagnostics, focusing on critical areas such as procalcitonin and proadrenomedullin. The company develops advanced diagnostic methods aimed at enhancing risk stratification for infections, cardiac diseases, and chronic conditions. By leveraging innovative biomarker technologies, B.r.a.h.m.s GmbH plays a vital role in improving patient outcomes through precise diagnostics, supporting healthcare professionals in making informed clinical decisions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

78 Patents

#1 in Hennigsdorf

#740 in Germany

#9,688 in the World

Hennigsdorf, Germany

B.r.a.h.m.s Gmbh

Forward Citations = 264

73 inventors:

Andreas Bergmann (49 out of 109 patents)

Joachim Struck (48 out of 65 patents)

Nils G Morgenthaler (18 out of 21 patents)

4. Jana Papassotiriou (13 out of 13 patents)

5. Darius Cameron Wilson (9 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: B.r.a.h.m.s Gmbh. Retrieved from https://idiyas.com/company/b-r-a-h-m-s

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…